Trial Profile
A Randomized, Double-Blind, Placebo- and Active-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of JNJ-42160443 as Monotherapy in Subjects With Moderate to Severe, Chronic Knee Pain From Osteoarthritis.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 13 Mar 2020
Price :
$35
*
At a glance
- Drugs Fulranumab (Primary) ; Oxycodone
- Indications Musculoskeletal pain
- Focus Therapeutic Use
- 01 Jun 2016 Primary endpoint has been met. (Pain intensity), as per an article published in the International Journal of Clinical Practice.
- 01 Jun 2016 Results published in the International Journal of Clinical Practice
- 11 May 2013 Results presented at the 32nd Annual Scientific Meeting of the American Pain Society.